Your browser doesn't support javascript.
loading
Extensive validation study of the Parkinson's Disease Composite Scale.
Martinez-Martin, P; Radicati, F G; Rodriguez Blazquez, C; Wetmore, J; Kovacs, N; Ray Chaudhuri, K; Stocchi, F.
Affiliation
  • Martinez-Martin P; National Center of Epidemiology, Carlos III Institute of Health, Madrid, Spain.
  • Radicati FG; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
  • Rodriguez Blazquez C; University and Institute for Research and Medical Care IRCCS San Raffaele, Roma, Italy.
  • Wetmore J; National Center of Epidemiology, Carlos III Institute of Health, Madrid, Spain.
  • Kovacs N; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
  • Ray Chaudhuri K; National Center of Epidemiology, Carlos III Institute of Health, Madrid, Spain.
  • Stocchi F; Department of Neurology, Medical School, University of Pecs, Pecs, Hungary.
Eur J Neurol ; 26(10): 1281-1288, 2019 10.
Article de En | MEDLINE | ID: mdl-31021043
ABSTRACT
BACKGROUND AND

PURPOSE:

A composite instrument able to rapidly and reliably assess the most relevant motor and non-motor afflictions suffered by Parkinson's disease (PD) patients in a real world clinic setting is an unmet need. The recently validated PD Composite Scale (PDCS) was designed to fulfil this gap as a quick, comprehensive PD assessment. The objective of this study was extensive evaluation of the PDCS's clinimetric properties using a large international sample.

METHODS:

This was a cross-sectional study in which the PDCS, the Movement Disorder Society Unified Parkinson's Disease Rating Scale and the Clinical Impression of Severity Index for PD were applied. Basic clinimetric attributes of the PDCS were analysed.

RESULTS:

In total, 776 PD patients were included. The PDCS total score showed negligible floor and ceiling effects. Three factors (54.5% of the variance) were identified factor 1 included motor impairment, fluctuations and disability; factor 2, non-motor symptoms; and factor 3, tremor and complications of therapy. Cronbach's alpha was from 0.66 to 0.79. Inter-rater reliability showed weighted kappa values from 0.79 to 0.98 for items and intraclass correlation coefficient values from 0.95 (Disability) to 0.99 (Motor and total score). The Bland-Altmann method, however, showed irregular concordance. PDCS standard error of measurement and convergent validity with equivalent constructs of other measures were satisfactory (≥0.70). PDCS scores significantly differed by Hoehn and Yahr stage.

CONCLUSION:

Overall, in line with previous findings, the PDCS is a feasible, acceptable, valid, reliable and precise instrument for quickly and comprehensively assessing PD patients.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Parkinson Type d'étude: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Eur J Neurol Sujet du journal: NEUROLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Espagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Parkinson Type d'étude: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Eur J Neurol Sujet du journal: NEUROLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Espagne
...